Search

everythinglearnresearchcommunity

for

Search:↓

Topical eye β-blockers might cause hair loss, which usually gets better after stopping the medication.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

FFA's causes may include environmental triggers and genetic factors.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Women with scarring alopecia have a lower quality of life and more anxiety and depression than those with non-scarring alopecia.

The study found that alopecia areata and hypothyroidism increase the risk of each other, but androgenetic alopecia and hypothyroidism do not.

Kidney transplant patients often have skin issues, mainly infections.

Some COVID-19 patients lose hair, with the most common type linked to male hormones and possibly increasing the risk of severe illness.

The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.

Topical JAK inhibitors may help treat some skin conditions but need more research.

People with atopic dermatitis are more likely to develop other skin conditions due to shared genetics and immune pathways.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Rare ULBP3 gene changes may raise the risk of Alopecia areata, a certain FAS gene deletion could cause a dysfunctional protein in an immune disorder, and having one copy of a specific genetic deletion is okay, but two copies cause sickle cell disease.

The document concludes that scalp conditions have various causes and can present in many different ways.

Sleep problems and skin issues affect each other; poor sleep can worsen skin conditions, and some skin treatments can improve or harm sleep quality.

Some COVID-19 pneumonia patients in Veracruz, Mexico, had skin issues, with reversible hair loss linked to disease severity.